Most Popular - California-based Questcor Pharmaceuticals (QCOR) gave investors a case of whiplash Tuesday after reporting a fantastic quarter, yet following up with news about pending investigations into … Continue Reading
Read nowLong Ideas - PropThink has been bullish on Questcor Pharmaceuticals (QCOR) for quite some time, and since our report highlighting the company’s prospects late last year, shares have … Continue Reading
Read nowLong Ideas - Questcor (QCOR) is getting some love Thursday morning following an announcement that the company will be pursuing the commercialization of H.P. Acthar Gel in respiratory … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals’ (QCOR) purchase of Synacthen on Tuesday, a synthetic melanocortin receptor agonist, from Novartis (NVS) is good news for the $2B drug developer, fortifying … Continue Reading
Read nowLong Ideas - The Bears may focus on the pushes and pulls around Questcor Pharmaceuticals’ (QCOR) 4Q 2012 earnings results, but the bottom line is, the earnings results … Continue Reading
Read nowLong Ideas - Shares of Questcor Pharmaceuticals (QCOR) have started to rise to more realistic valuations in the new year (as PropThink expected), breaking $31 dollars on Tuesday … Continue Reading
Read now- Rumors percolated today – pushing QCOR down nearly $9/share – that a conference call to be hosted by a Broker-Dealer would feature an expert discussing … Continue Reading
Read now